Clinical evaluation of satigrel in intermittent claudicators.
Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti-thrombotic effect in various animal thrombosis models. The present study assessed the effect of oral satigrel on cutaneous circulation in patients with intermittent claudication due to arteriosclerosis obliterans. Prospective clinical trial with more than 4 weeks follow-up. Outpatient department of a university hospital. Ten patients with intermittent calf claudication were studied (14 limbs with obstruction, 6 limbs without obstruction, and chest wall). After giving informed consent and one week wash-out of effected agents, a 2 mg oral dose of satigrel twice daily was administered for more than 4 weeks. Transcutaneous partial pressure of oxygen (PtcO2), skin temperature, ankle pressure, and the treadmill test were determined just before therapy, after 2 and 4 weeks of satigrel therapy, and at treatment termination. The paired student's t-test was used for statistical analysis. The PtcO2 in the foot of the ischemic leg showed a significant increase at the end of therapy compared with before therapy (p < 0.05). Skin temperature showed a significant difference in both the ischemic and healthy legs. The walking distance was also significantly extended at therapy termination. Satigrel improved the cutaneous circulation and symptoms of patients with intermittent claudication.